Author Archive
Congratulations to New Executive Committee Members
Wednesday, March 21st, 2018ISCTM was honored to have so many members interested in standing for election to the Executive Committee. Serving on this committee requires quite a commitment of time and energy. It is satisfying to know how many of you find the work we do valuable enough to want to serve your colleagues by investing yourselves in the Society. Those who won the vote this year were: Judith Jaeger, Antony Loebel, Luca Pani and Amir Kalali who was re-elected to a second term. And congratulations to our new President, Carla Canuso and many thanks to Stephen Marder for his excellent leadership over the past two years. VIEW 2018-2019 Executive Committee.
2018 Autumn Online Confirmation and Agreement
Wednesday, March 14th, 2018Autumn 2018 Speakers’ Corner
Wednesday, March 14th, 2018Thank you for agreeing to participate as a presenter and/or chairperson at the upcoming ISCTM 2018 Autumn Conference. This page contains all the links you will need for submitting information to the ISCTM, as well as information we hope you find helpful for your planning.
Dates/Location
15-16 October 2018
The Ritz-Carlton Hotel
Marina del Rey, California
(Housing to be booked through ISCTM during registration process. Do not contact the hotel directly.
Details below)
STEP 1: Complete the Online Confirmation and Agreement
STEP 2: Please Email Biographical Paragraph and Photo
2500 characters max (including spaces)
STEP 3: Register for the Meeting
Registration announcements will be sent in JUNE. We will send a reminder to register at that time. Selecting Register from that email will direct you to the fee-waived Speaker Registration path. You will have the opportunity to book your housing during the registration process. Do not contact the hotel. To have the email resent please email the Secretariat.
STEP 4: Please Email Abstract
Abstract, for inclusion in the program book, should be submitted after the first session development call with chairs, but no later than 7 September 2018. Abstract should be in paragraph form,
< 300 words and contain no tables.
STEP 5: Presentation Submission Schedule
— Draft: Chairs will advise according to each segment’s agenda development telecon schedule.
— Final: Bring flash drive to onsite registration desk the morning of your session, no later than 30 minutes prior to the start of the meeting day.
STEP 6: Chairs/Co-Chairs – Publication Information
To facilitate dissemination of information discussed during ISCTM meetings, we encourage publications from ISCTM sessions. Chairs will discuss during the session development calls. (Output category specifications)
Travel Arrangements:
We ask speakers who will request reimbursement to book flights enough ahead of travel dates to take advantage of the lower fares. In order to meet ISCTM’s fiscal responsibilities, the Society endeavors to operate its meetings as close to break even as possible, hopefully in the black. The Executive does not wish to raise additional revenue through increasing registration fees, so we must keep a close watch on expenses. (ISCTM Speaker Reimbursement Policy)
Preliminary Agenda:
| Day 1: Monday, 15 October |
|
| 7:00 am | Registration opens/Continental Breakfast |
| 8:00 | Presidential Welcome |
| 8:15-12:15 | Innovative Uses of Technology for Measuring Outcome in Clinical Trials- Part 1 |
| 12:15-1:30 | Lunch |
| 1:45-5:30 | Innovative Uses of Technology for Measuring Outcome in Clinical Trials-Part 2 |
| 6:00-7:30 | Poster Session/Reception |
| Day 2: Tuesday, 16 October |
|
| 7:00 am | Registration opens |
| 7:30-9:30 | Workshop Breakfasts |
| 9:45-12:45 | Parallel Sessions |
| a) Biomarkers in psychiatric drug development: an update | |
| b) Designing trials using gene therapy for neurological disorders with a clear genetic basis | |
| 12:45-1:30 | Lunch |
| 1:45-4:00 | Biomarkers technologies for clinical trial design and regulatory strategies in neurodegenerative disorders |
| 4:00 | Meeting Adjourns |
ISCTM Contact Information
George Haig – Chair, Scientific Program Committee
Carlotta McKee – Executive Director, ISCTM
Mary Bea Harding – Associate Director, ISCTM
Robin Patterson – Administrative Assistant, ISCTM
Phone: +1.615.383.7688
2019 New Investigator Award: Submission and Eligibility Guidelines
Thursday, March 8th, 2018The International Society for CNS Clinical Trials and Methodology has created a program to recognize promising new investigators across the broad range of methodological, regulatory and substantive programmatic interests of the society. Up to four (4) NI Award applicants will be selected each year. Appointments as NI Awardees will be for one year.
(Previous Award Recipients)
Eligibility Criteria: Early career (second-year or beyond postdocs or those within 8 years of the completion of training) academic or (more…)
2018 Autumn Conference – Poster Submission Details and Guidelines
Tuesday, February 6th, 2018ISCTM 2018 Autumn Conference
15-16 October 2018
The Ritz-Carlton
Marina del Rey, CA USA
IT IS IMPORTANT THAT YOU REVIEW GUIDELINES.
The ISCTM Poster Committee is calling for Abstracts with content pertaining to significant CNS methodological problems-solutions relevant to the meeting program topics or previous ISCTM topics. ABSTRACTS AND POSTERS MUST BE FREE OF COMMERCIAL BIAS OR PROMOTION. (Please see Guidelines)
Submission Process: You may submit your Abstract online by filling out the form provided below or by EMAIL. If submitting by email, please be sure to include all requested information. You will receive a confirmation of receipt.
Submission Deadline: Abstracts should be submitted no later than Wednesday, 1 August 2018, for review by the ISCTM Poster Committee.
Notification: You will be notified of the committee’s decision on or before Monday, 27 August 2018.
Meeting Dates: 15-16 October 2018
Formal poster session: Monday, 15 October 2018.
Presenter must register for the meeting and attend the formal session. Poster session is part of the Scientific Program. ISCTM recommends that the poster be presented by the first author. If that is not possible, please designate which author will be present at the session to discuss the work with attendees.
Poster set up: Monday during lunch. Poster order (board number) will be included in the Poster Abstract section of the Meeting Program booklet. Numbers will not be distributed prior to the meeting.
Poster removal: Posters should be removed at the conclusion of the formal Poster Session.
Location: The Ritz Carlton, Marina del Rey – Marina Vista room
Poster Review: Certificates of Recognition will be awarded. In order to facilitate judging, please forward .pdf of poster to Secretariat for review by judging committee no later than Monday, 8 October. Posters of awardees will be published on the ISCTM website.
Poster Dimensions: Poster boards are Horizontal. Posters should not exceed 4’ (122 cm) Vertical by 6’ (183 cm) Horizontal. As the poster session is small, it is not necessary to include the presentation number on your poster.
(Refer to Guidelines link above for additional formatting information)
Shipping Information:
The Ritz-Carlton, Marina del Rey
4375 Admiralty Way
Marina del Rey, CA 90292
Attention: Guest- Receiver’s Name
Guest’s arrival date at hotel
ABSTRACT SUBMISSION FORM
Submission should contain:
- Title, all authors, author affiliations
- Methodological Question being addressed
- Abstract content should be formatted into sections as outlined in the Guidelines, with word count up to 500 exclusive of title, authors, affiliations.
- Please review Guidelines before submitting abstract.
If you are submitting abstract on behalf of author, please be sure to enter your name and email under Submitter. Thank you.
Unresolved Problems in Neuroscience Drug Development
Wednesday, January 10th, 2018Chair: Amir Kalali, MD
Topic Leads: Adam Butler, Gary Sachs, MD
This session will feature a couple of yes/no questions where there are a lot of data and even more opinions to support either yes or no response. These will be discussed in a point-counterpoint manner. Audience participation is welcome. The first topic is around whether amyloid remains a viable target for neurodegenerative diseases. There have been a few reported failures with compounds that inhibit or limit amyloid, on the other hand supportive data remain strong. Dr. Jim Hendrix from the Alzheimer’s Association Global Science Initiatives will argue in favor of continued pursuit of amyloid, and Michael Gold from AbbVie will argue in favor of its demise. The second topic is around whether increasing sample sizes in clinical trials affords greater precision in detecting treatment effects. Another way of stating the question is whether bigger studies are better? Stephen Brannan of Karuna Pharmaceuticals will argue against. Dr. Andrew Potter of the FDA will also give perspective.
14th Annual Scientific Meeting Supporters
Thursday, January 4th, 2018
Thanks to the The Michael J. Fox Foundation for its support of the collaborative session:
Innovative Approaches for Slowing Disease Progression in Parkinson’s Disease
22 February 2018, The Fairmont, Washington DC
Direct me to the ISCTM 14th Annual Scientific Meeting Archive
14th Annual Scientific Meeting Posters
Wednesday, December 6th, 2017Poster PDFs and abstracts are in alphabetical order by author.
Thank You
Thursday, November 16th, 2017Thank you for completing this survey.
Use of Regulatory Databases as Exemplars for Improving Randomized Clinical Trial Efficiency: Can the model be extended?
Thursday, November 9th, 2017Chairs: Tiffany Farchione, MD; Heddie Martynowicz, DM, MS
This session will examine approaches for using data from existing regulatory databases to improve the methodology for future CNS clinical trials and highlight work by regulatory colleagues from the Food and Drug Administration (FDA), and the European Medicines Agency (EMA) in utilizing their databases to answer regulatory questions. Strengths and limitations of this work will be discussed with an eye to building on this work and expanding it to new areas. Industry perspectives and potential opportunities for industry/regulatory agency collaborations to answer questions from their large data sets will also be presented. The session will conclude with a panel discussion where representatives from FDA, EMA, academia, and industry will discuss limitations, gaps, and future opportunities for using existing databases to improve the methodology for CNS clinical trials.